Reversal of signs and symptoms of a B-cell lymphoma in a patient using only low-dose naltrexone

Integrative Cancer Therapies

Volumn 6, Issue 3, 2007, Pages 293-296

  Berkson, Burton M ^a   Rubin, Daniel M ^b   Berkson, Arthur J ^c  

^a Integrative Medical Center of New Mexico   (United States)

^b Naturopathic Specialists   (United States)

^c Scottsdale Medical Pavilion ^*

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE; THIOCTIC ACID;

ADULT; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CERVICAL LYMPH NODE; DIET THERAPY; DISEASE FREE SURVIVAL; FOLLICULAR LYMPHOMA; HUMAN; INGUINAL LYMPH NODE; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NUTRITIONAL SUPPORT; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NALTREXONE;

EID: 34548136988     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735407306358     Document Type: Article

References (14)

1. Berkson BM, Rubin DM, Berkson AJ The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther. 2006 ; 5 (1). 83-89.
2. Freedman AS, Harris NL Clinical and pathologic features of follicular lymphoma. www.uptodate.com. Accessed June 5, 2007.
3. Hennessy BT, Hanrahan EO, Daly PA Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004 ; 5: 341-353.
4. Ott OJ, Rodel C., Gramatzki M., et al. Radiotherapy for stage I-III nodal low-grade non-Hodgkin's lymphoma. Strahlenther Onkol. 2003 ; 179: 694-701.
5. van Oers MH, Klasa R., Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006 ; 108 (10). 3295-3301.
6. Jankovic BD, Radulovic J. Enkephalins, brain and immunity: modulation of immune responses by methionine-enkephalin injected into the cerebral cavity. Int J Neurosci. 1992 ; 67 (1-4). 241-270.
7. Bihari B. Efficacy of low dose naltrexone as an immune stabilizing agent for the treatment of HIV/AIDS [letter]. AIDS Patient Care. 1995 ; 9 (1). 3.rt
8. Smith JP, Stock H., Bingaman S., Mauger D., Rogosnitzky M., Zagon IS Low-dose naltrexone improves active Crohn's disease. Am J Gastroenterol. 2007 ; 102 (4). 820-828.
9. Bihari B. LDN and cancer. Low Dose Naltrexone Web site. http://www.lowdosenaltrexone.org. Accessed June 5, 2007.
10. Mathews PM, Froelich CJ, Sibbitt WL, Bankhurst AD Enhancement of natural cytotoxicity by beta-endorphin. J Immunol. 1983 ; 130 (4). 1658-1662.
11. Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. Microvasc Res. 006; 72 (1-2). 3-11. http://www.clinicalpharmacology.com/apps/ default.asp?entry=11&rNum=430.
12. Zagon IS, McLaughln PJ Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983 ; 221: 671-673.
13. Zagon IS, McLaughlin PJ Opioids and the apoptotic pathway in human cancer cells. Neuropeptides. 2003 ; 37: 79-88.
14. Lissoni P., Meregalli S., Fossati V., et al. Radioendocrine therapy of brain tumors with the long acting opioid antagonist naltrexone in association with radiotherapy. Tumori. 1993 ; 79: 198-201.